The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

Imprimis NJOF is issuing a recall for the following products:

- **Product Name:** Epinephrine-Lidocaine (0.25 mg/mL, 5 mg/mL) Preservative-Free Intraocular Solution for Injection (Epi/Lido)

Description: Single-Use Sterile Intraocular Solution for Injection

NDC: 71384-640-01

- **Product Name:** Dexamethasone-Moxifloxacin Intraocular Solution for Injection, 1 mg/mL, 5mg/mL (DM)

Description: Single-Use Sterile Intraocular Solution for Injection

NDC: 71384-512-01

- **Product Name:** Dexamethasone-Moxifloxacin- Ketorolac Intraocular Solution for Injection, 1mg/mL, 0.5 mg/mL, 0.4 mg/mL (DMK)

Description: Single-Use Sterile Intraocular Solution for Injection

NDC: 71384-513-01

- **Product Name:** Moxifloxacin Intraocular Solution for Injection, 8 mg/0.8 mL (Moxi 0.8 mg/0.8mL)

Description: Single-Use Sterile Intraocular Solution for Injection

NDC: 71384-509-08

- **Product Name:** Moxifloxacin Intraocular Solution for Injection, 4 mg/0.8 mL (Moxi 4 mg/0.8 mL)

Description: Single-Use Sterile Intraocular Solution for Injection

NDC: 71384-511-08

During a recent FDA inspection, investigators observed deficient standard operating procedures concerning a component of the firm’s visual inspection program.

Imprimis' assessment of this issue revealed "the likelihood of a health hazard is unlikely" however, out of an abundance of caution, Imprimis NJOF ("Imprimis") has initiated a voluntary recall of all unexpired lots that are impacted by this visual inspection observation.

All affected lots obtained passing results for sterility, potency, endotoxin testing, identification, minimum fill, finished product pH, and description/color/clarity testing prior to release. Additionally, each lot was fully reviewed and dispositioned by members of the Quality Assurance department before release. Furthermore, no adverse drug events were received that directly correlated to the issue at hand.

Lot Numbers:

Product	Lot Number	Date Compounded	Expiry Date	Distribution Date Ranges	
Epi/Lido	23APR033	05/08/23	5/1/2024	7/24/2023	8/9/2023
	23JUN001	06/12/23	6/5/2024	8/21/2023	9/13/2023
DM	23MAY016	05/13/23	5/8/2024	7/19/2023	9/14/2023
	23JUL016	07/17/23	7/10/2024	9/8/2023	12/27/2023
	23AUG034	08/23/23	8/16/2024	12/13/2023	1/15/2024
	23DEC014	12/17/23	12/10/2024	12/28/2023	3/14/2024
DMK	23MAY008	05/08/23	5/1/2024	7/5/2023	9/29/2023
	23OCT011	11/02/23	10/26/2024	12/4/2023	12/26/2023
	23NOV035	12/13/23	12/6/2024	12/26/2023	3/14/2024
	24JAN024	01/21/24	1/14/2025	3/13/2024	4/16/2024
Moxi 0.8 mg/0.8mL	23OCT013	10/17/23	10/10/2024	12/29/2023	1/24/2024
Moxi 4 mg/0.8 mL	23JUN003	06/05/23	5/29/2024	8/11/2023	9/6/2023
	23JUL035	07/31/23	7/24/2024	9/6/2023	10/17/2023
	23AUG033	08/21/23	8/14/2024	10/17/2023	11/17/2023
	23AUG043	08/28/23	8/21/2024	11/6/2023	11/27/2023
	23SEP001	10/03/23	9/26/2024	11/27/2023	12/14/2023
	23OCT002	10/11/23	10/4/2024	12/8/2023	1/24/2024
	23OCT031	11/07/23	10/31/2024	1/24/2024	2/12/2024

23NOV011	12/05/23	11/28/2024	2/12/2024	2/29/2024
24FEB027	02/22/24	2/15/2025	4/2/2024	4/18/2024